Loading…
← CockpitCompetitor Analysis › 300026.SZ Tianjin Chase Sun Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Tianjin Chase Sun Pharmaceutical Co., Ltd. Class A300026.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Tianjin pharma group known for Xuebijing, a TCM injection used in hospital intensive-care and sepsis treatment.

≈ A Chinese hospital-injectable TCM makerMomentum strong 65
Mkt cap
$1.23B
US dollars, full cap
Free float
52%
of shares outstanding
$/day
$15.3M
20-day average traded
Fwd P/E
21.3×
forward earnings
ROIC−WACC
-4.0 pp
WACC 7.6%
Hurdle
+12 pp
Req g minus delivered
Close · CNYCN¥3.00
1D-0.3%
1W-4.8%
1M-5.1%
3M-20.2%
6M-9.6%
YTD-14.8%
1Y-21.7%
ATR %2.4%
52w lowhigh24.8% off high

What Tianjin Chase Sun Pharmaceutical does

Tianjin pharma group known for Xuebijing, a TCM injection used in hospital intensive-care and sepsis treatment.

Sells Xuebijing, a Chinese-medicine injection given in hospital intensive care, to hospitals through distributors, so sales depend on staying on China's reimbursement lists and on how widely doctors use it. A retail pharmacy chain adds a second line selling other makers' medicines to consumers.

In one line: A Chinese hospital-injectable TCM maker.

Products and services

  • Xuebijing injection (sepsis/critical care)
  • Retail pharmacy chain
  • Other TCM products

Customers

  • Hospitals (ICU/critical care)
  • Retail pharmacies

Where it sits in the supply chain

  • Pharmaceuticals
  • Traditional Chinese medicine
  • Hospital injectables

What could go right

  • ICU/sepsis treatment volume growth
  • Pharmacy retail expansion

What could go wrong

  • TCM injectable safety scrutiny
  • Reimbursement price cuts

Moat: narrow (brand, regulatory licence). Established hospital-injectable brand with wide ICU adoption and reimbursement listing.

Headquarters: Tianjin, China · Employees: 4,852

Named competitors

Tianjin Chase Sun Pharmaceutical at a glance

Size Tianjin Chase Sun Pharmaceutical (300026.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.23B, the 1818th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥3.00 on 18 Nov 2026.

Performance Over six months the shares fell 9.6%, against -22.2% for the median peer and -20.0% for the China market (cap-weighted) — 8th highest of 21 in its peer set.

Growth Revenue fell 29.0% over the last twelve months (peer median +7.6%); the operating margin is 2.8% (peer median -18.6%).

Valuation It trades at 21.3× forward earnings against a peer median of 22.1× (5th cheapest of 10).

Price implies For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is -5%, so the hurdle is +12 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 4.0 points below its cost of capital (7.6% WACC).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026300026.SZ 91Peer median 78
Six months, rebased to 100: Tianjin Chase Sun Pharmaceutical against the median of its 20 peers (local-currency closes).

Tianjin Chase Sun Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥3.90BCN¥4.90BCN¥5.74BCN¥6.07BCN¥6.61B
Revenue growth—-15%-5%-8%—
Gross profitCN¥2.61BCN¥2.65BCN¥2.81BCN¥3.07BCN¥3.60B
EBITDAn/aCN¥523MCN¥447MCN¥862MCN¥1.06B
Net incomeCN¥25.8MCN¥18.5MCN¥21.5MCN¥507MCN¥624M
Free cash flowCN¥659MCN¥681MCN¥654MCN¥1.18B-CN¥23.2M
Capital expenditureCN¥110MCN¥130MCN¥193MCN¥347MCN¥770M
Total debtCN¥374MCN¥540MCN¥897MCN¥1.58BCN¥2.13B

Quarterly statements and history in the cockpit →

Tianjin Chase Sun Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%-10%0%+10%IDIAAVLN347850GPCR000950HROW2616300006688076GHRS2493300204AMPH688321688443NKTR6855002332000989301263300026.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Tianjin Chase Sun Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%0×200×400×000950HROW688076300204AMPH688321002332000989301263300026.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Tianjin Chase Sun Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%300006688076AMPH002332000989300026.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Tianjin Chase Sun Pharmaceutical is the large dot.

Tianjin Chase Sun Pharmaceutical competitors and peer comparison

Head to head with its named competitors (300026.SZ vs 002603.SZ vs 600535.SS vs 000999.SZ)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Tianjin Chase Sun Pharmaceutical 300026.SZ$1.23B-10%-29%3%21.3×7.0%
Shijiazhuang Yiling Pharmaceutical 002603.SZ$3.83B-7%+32%21%17.5×-3.9%
Tasly Pharmaceutical 600535.SS$3.19B-2%-4%19%16.7×-7.5%
China Resources Sanjiu Medical & Pharmaceutical 000999.SZ$6.59B+6%+4%14%13.2×-6.2%

How Tianjin Chase Sun Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Tianjin Chase Sun Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure300026.SZPeer medianRank in peer set
1-month return-5.1%-6.2%9th highest of 21
6-month return-9.6%-22.2%8th highest of 21
Distance from 52-week high-24.8%-42.2%4th highest of 21
Revenue growth (TTM)-29.0%+7.6%2nd lowest of 18
Operating margin2.8%-18.6%6th highest of 18
Forward P/E21.3×22.1×5th cheapest of 10
Growth the price implies (Req g, 7 yrs)7.0%2.5%2nd most demanding of 6
Growth delivered (Del g)-5.3%-1.3%3rd lowest of 6
Hurdle (Req g minus delivered)+12.3 pp+1.0 pp2nd most demanding of 6
ROIC minus cost of capital-4.0 pp-9.4 pp6th highest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Tianjin Chase Sun Pharmaceutical 300026.SZChina$1.23B-10%-29%3%21.3×7.0%-5.3%
Idorsia IDIA.SWSwitzerland$1.22B-9%-5%-70%n/an/an/a
Avalyn Pharma AVLNUnited States$1.23B-1%n/an/an/an/an/a
D&D Pharmatech 347850.KSSouth Korea$1.22B-49%-77%-2,324%n/an/an/a
Structure Therapeutics, Inc. Sponsored ADR GPCRUnited States$1.24B-53%n/an/an/an/an/a
C.Q. Pharmaceutical 000950.SZChina$1.24B-27%-3%1%18.6×n/an/a
Harrow HROWUnited States$1.21B+4%+21%1%26.8×n/an/a
CStone Pharmaceuticals 2616.HKHong Kong$1.21B-22%+117%-89%n/an/an/a
Chongqing Lummy Pharmaceutical 300006.SZChina$1.21B+26%-6%-19%n/a44.1%-13.2%
Sinopep-Allsino Bio Pharmaceutical 688076.SSChina$1.25B-16%+14%19%11.9×3.4%+27.9%
GH Research GHRSUnited States$1.25B-19%n/an/an/an/an/a
Mabwell (Shanghai) Bioscience 2493.HKHong Kong$1.20B-29%+21%-127%n/an/an/a
Staidson (Beijing) Biopharmaceuticals 300204.SZChina$1.26B-41%-24%-51%522.3×n/an/a
Amphastar Pharmaceuticals AMPHUnited States$1.27B+64%+3%19%9.1×2.5%+15.5%
Shenzhen Chipscreen Biosciences 688321.SSChina$1.18B-38%+27%12%60.4×n/an/a
Chongqing Genrix Biopharmaceutical 688443.SSChina$1.18B-22%+256%-27%n/an/an/a
Nektar Therapeutics NKTRUnited States$1.18B-50%-17%-304%n/an/an/a
Ascentage Pharma Group International 6855.HKHong Kong$1.18B-34%+70%-220%n/an/an/a
Zhejiang Xianju Pharmaceutical 002332.SZChina$1.28B-1%+8%11%17.7×-0.4%-1.3%
Jiuzhitang 000989.SZChina$1.16B-7%+46%19%22.1×-4.0%-9.0%
Guangdong Taienkang Pharmaceutical 301263.SZChina$1.30B-24%+2%-2%60.7×n/an/a

Questions

Who are Tianjin Chase Sun Pharmaceutical's main competitors?
Named competitors: Yiling Pharmaceutical (002603.SZ), Tasly Pharmaceutical (600535.SS), China Resources Sanjiu (000999.SZ). The cockpit's measured peer set (industry) also includes Idorsia (IDIA.SW), Avalyn Pharma (AVLN), D&D Pharmatech (347850.KS), Structure Therapeutics, Inc. Sponsored ADR (GPCR), C.Q. Pharmaceutical (000950.SZ), Harrow (HROW).
Is Tianjin Chase Sun Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 21.3× against a peer median of 22.1×, 5th cheapest of 10 in its peer set. For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is -5%, so the hurdle is +12 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Tianjin Chase Sun Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -9.6% against -22.2% for the median peer; over one year -21.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.